We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BSL:ASXBluescope Steel Limited Analysis

Data as of 2026-06-13 - not real-time

A$33.48

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

BlueScope Steel has ridden a ~40% rally over the past six months, propelled by improving earnings and lingering takeover speculation. Technical signals remain bullish – the 20‑day SMA sits above the 50‑day SMA, the MACD line is above its signal, and price is trading above the 200‑day SMA, while a high RSI signals near‑term overbought conditions. Support around $29.24 and resistance near $34.14 frame the current $33.48 price, suggesting limited upside in the immediate term.
Fundamentally, revenue growth is modest at 4% with thin operating margins, while the debt‑to‑equity ratio is elevated and the payout ratio exceeds 100%, raising concerns about dividend sustainability. Nevertheless, the stock trades at a high trailing PE (~58x) but a more reasonable forward PE (~15x) and offers a 2.84% dividend yield. Analyst consensus leans "buy" with a mean target of $32.08 and a median of $33.40, indicating the market expects modest further upside despite valuation pressures.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical resistance with RSI indicating overbought
  • Stable but high volatility (≈25% 30‑day)
  • Dividend payout ratio >100% may prompt adjustment

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Bullish moving‑average crossover and MACD alignment
  • Forward earnings estimate improves PE to ~15x
  • Analyst consensus and upside potential to median target $33.40

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Diversified geographic footprint reduces single‑region exposure
  • Steady dividend yield despite high payout ratio
  • Fundamental recovery supported by modest revenue growth and operating cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin1.78%
P/E Ratio58.7
ROE3.43%
ROA3.69%
Debt/Equity9.45
P/B Ratio1.4
Op. Cash FlowA$1.6B
Free Cash FlowA$48.1M

Technical Analysis

TrendBullish
RSI69.4
SupportA$29.24
ResistanceA$34.14
MA 20A$31.46
MA 50A$30.04
MA 200A$26.30
MACDBullish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair ValueA$1.72
Target PriceA$32.08
Upside/Downside-4.18%
GradeFair
TypeBlend
Dividend Yield2.84%

Risk Assessment

Beta0.68
Volatility25.38%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.